JP Morgan Chase’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

JP Morgan Chase’s Portfolio DICE Stock Details DICE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-215,300	Closed	-$10M	–	7857
2023 Q2	$10M	Buy	+215,300	New	+$7.44M	﹤0.01%	2287
2022 Q4	–	Sell	-465,000	Closed	-$9.43M	–	7204
2022 Q3	$9.43M	Buy	465,000 +315,000	+210%	+$5.74M	﹤0.01%	2194
2022 Q2	$2.33M	Buy	+150,000	New	+$2.58M	﹤0.01%	3409

JP Morgan Chase's DICE Position: Q3 2023 in Review

JP Morgan Chase sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q3 2023, closing a stake of 618,089 shares — an estimated $28.7M sold.

JP Morgan Chase first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $28.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

JP Morgan Chase reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
JP Morgan Chase sold 618,089 DICE Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $28.7M.
JP Morgan Chase first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2021 and held it in 7 quarters.
JP Morgan Chase's DICE Therapeutics, Inc. Common Stock position peaked at $28.7M in Q2 2023.
0 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.